ArticleAnnals of surgery open : perspectives of surgical history, education, and clinical approaches2025
Intensive Surveillance and Aggressive Multimodal Treatment for Liver Metastases From Uveal Melanoma.
Article in Annals of surgery open : perspectives of surgical history, education, and clinical approaches, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Combination of Three Herbal Components (ISL, Que, Meth) Suppresses Uveal Melanoma Growth via Gαq/MEK/YAP Axis Modulation and Apoptosis.Biomedicines · 2026Article
- Characteristics and Outcomes of Patients with Early or Late Uveal Melanoma Metastasis: A Review.Ocular oncology and pathology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We evaluated a cohort of patients with liver metastasis from uveal melanoma (LMUM) to assess the benefit of intensive surveillance and multimodal treatment on overall survival. Background: LMUM is typically associated with a poor prognosis. Patients and methods: This two-center retrospective cohort study from January 2010 to December 2024 included 58 patients with LMUM deemed to be oligometastatic and referred for surgical management. Overall survival after treatment of LMUM and primary uveal melanoma was determined using Kaplan-Meier methods and the Cox proportional hazards method. Results: Fifty-eight patients [performance status (PS): PS1 = 11, PS0 = 47] with oligometastatic LMUM were screened to stratify patients with multifocal disease not undergoing liver surgical/ablative treatment (Group A, n = 27) and those with oligometastatic liver disease having liver resection/ablation (Group B, n = 31) along with systemic treatment as per patient/physician choice. Patients in Group B had longer liver-specific overall survival [Group B: OS = 45.1 (95% confidence interval (CI) = 33.5-not reached] months; Group A, median 18.6 (95% CI = 13.8-23.8) months; Conclusions: Intensive surveillance for early diagnosis of oligometastatic LMUM and its relapse along with surgical resection/ablation and systemic treatment facilitates long-term remission. This retrospective case series requires prospective validation in a multicenter cohort study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.